Abstract: The present invention relates to nucleic acid sequence which comprises the genome of an infectious GB virus B clone. The invention also relates to the use of the nucleic acid sequence of the infectious GB virus B clone to indirectly study the molecular properties of HCV, and in the production of HCV/GBV-B chimeras. The invention further relates to the use of the infectious nucleic acid sequence of GB virus B clone and the HCV/GBV-B chimeras in the development of vaccines and therapeutics for HCV.
Type:
Grant
Filed:
June 2, 2000
Date of Patent:
October 31, 2006
Assignee:
The United States of America as represented by the Department of Health and Human Services
Inventors:
Jens Bukh, Masayuki Yanagi, Suzanne U. Emerson, Robert H. Purcell
Abstract: Compounds of formula (I), and pharmaceutically acceptable salts and esters thereof: (I); wherein Q, R2, X, Y and Z are as defined herein; are inhibitors of the hepatitis C virus (HCV) NS3 protease
Type:
Grant
Filed:
March 26, 2002
Date of Patent:
October 10, 2006
Assignee:
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti SpA
Inventors:
Stefania Colarusso, Cristina Gardelli, Benjamin Gerlach, Steven Harper, Uwe Koch, Victor Giulio Matassa, Ester Muraglia, Frank Narjes, Jesus Maria Ontoria Ontoria, Alessia Petrocchi, Simona Ponzi, Ian Stansfield, Vicenzo Summa
Abstract: The invention concerns novel compounds capable of modulating the activity and stimulating the production of catalytic antibodies. More particularly, the invention concerns a compound capable of increasing the activity of an antibody having specific affinity for the catalytic site of the antibody, and it is not immunogenic. Such compounds are useful in particular for therapeutic treatment or prevention of a pathology related to an enzymatic deficiency, to stimulate in vivo hydrolysis of xenobiotics, drugs, medicines or any other molecule potentially toxic for the organism or for preventing or inhibiting allergic reactions.
Type:
Grant
Filed:
November 17, 2003
Date of Patent:
September 19, 2006
Assignee:
Gradient
Inventors:
Alain Friboulet, Berangere Avalle-Bihan, Helene Debat, Daniel Thomas
Abstract: Nutritional solutions and methods of making same are disclosed. The solutions include protein, lipid, and a carbohydrate source including high amylose starch and guar gum.
Type:
Grant
Filed:
April 13, 2000
Date of Patent:
August 1, 2006
Assignee:
Nestec S.A.
Inventors:
Eileen C. Fuchs, Chandrasekhara Reddy Mallangi, Kjerstin Carlsson, Axel Syrbe, Reinhard Behringer
Abstract: Pegylated T1249 polypeptide compounds are provided. Also provided are pharmaceutical compositions containing pegylated T1249 polypeptide compounds, and methods of making. Further provided are methods of inhibiting HIV infection using such compounds and compositions.
Abstract: The invention relates to biologically active molecules, interacting with thrombin and inhibiting the same. The invention particularly relates to molecules of general formula:Y1—(NH—X1—C?O)—(NH—X2—C?C)—(NH—X3—C?O)NH—X4—C?O)—(NH—X5—C?O)—(NH—X6—C?O)—Y2, in which Y1, Y2, and X1-6 have the meanings given in the description, N or C-terminal shortened variants of said compounds and the use thereof for the production of medicaments.
Abstract: The invention relates to new basic amino acid derivatives of general formulae I, II and III, and the preparation and use thereof in treatment of pain. The compounds have histogranin-like antinociceptive, morphine potentiating and COX-2 induction modulating activities.
Type:
Grant
Filed:
March 14, 2005
Date of Patent:
July 11, 2006
Assignee:
University of Ottawa
Inventors:
Simon Lemaire, Irma Bernatchez-Lemaire, Hoang-Thanh Le
Abstract: Disclosed is a class of compounds which inhibit the enzymatic conversion of fructose-lysine into fructose-lysine-3-phosphate in an ATP dependent reaction in a newly discovered metabolic pathway. According to the normal functioning on this pathway, fructose-lysine-3-phosphate (FL3P) is broken down to form free lysine, inorganic phosphate and 3-deoxyglucosone (3DG), the latter being a reactive protein modifying agent. 3DG can be detoxified by reduction to 3-deoxyfructose (3DF), or it can react with endogenous proteins to form advanced glycation end-product modified proteins (AGE-proteins). Also disclosed are therapeutic methods of using such inhibitors to treat glycogen storage diseases, including Fanconi's syndrome, as well as other pathological conditions resulting from the formation of AGE-proteins.
Abstract: Methods of use of pharmaceutical compositions and novel peptides which are conformationally constrained backbone cyclized somatostatin analogs, having somatostatin receptor subtype selectivity, are disclosed. These patterns or receptor subtype selectivity provide compounds having improved therapeutic utility. Methods for synthesizing the somatostatin analogs and for screening of the somatostatin analogs are also disclosed. Furthermore, pharmaceutical compositions comprising somatostatin analogs are disclosed.
Type:
Grant
Filed:
August 12, 2004
Date of Patent:
June 13, 2006
Assignee:
DeveloGen Israel Ltd.
Inventors:
Vered Hornik, Michel M. Afargan, Gary Gellerman
Abstract: A composition for counteracting and controlling hair loss having a menthol solution combined with Polysorbate 80 or 60 and lupine protein, with the optional admixture of petroleum jelly as a thickening agent.
Abstract: Agents for promoting bone deposition and growth in a mammalian subject. The agents are O-glycosylated and non-glycosylated peptides that are derived from vitamin D binding protein, collectively referred to hereinafter as “DBP” peptides. The DBP peptides are from 3 to 18, preferably from 4 to 14 amino acids in length and comprise a sequence which is at least 80% identical, preferably at least 90% identical to the amino acid sequence of a fragment contained within domain III of DBP. Methods for promoting bone deposition in a subject in need of the same are also provided. The methods comprise administering to the subject a therapeutically effective quantity of an agent selected from the group consisting of an activated form of vitamin D binding protein referred to hereinafter as “ADBP”, one or more DBP peptides, and combinations thereof. The agents may be administered locally or systemically.
Type:
Grant
Filed:
November 9, 2001
Date of Patent:
May 2, 2006
Assignees:
Northeastern Ohio Universities College of Medicine, Temple University
Inventors:
Gary B. Schneider, Steven N. Popoff, Fayez Safadi
Abstract: Use of high density lipoprotein and/or derivatives in the manufacture of a medicament for the prevention or treatment of organ dysfunction following ischaemia and reperfusion injury. In particular, the medicament may be for the treatment of end stage organ injury or failure.
Type:
Grant
Filed:
August 16, 2000
Date of Patent:
February 14, 2006
Assignee:
ZLB Behring AG
Inventors:
Gillian Cockerill, Norman Miller, Christoph Thiemermann, Michelle MacDonald
Abstract: A pro-drug comprising a cyclic undecapeptide wherein the peptide chain thereof comprises at least one amino acid residue, useful as a medicinal product, including use for treatment of pathological conditions of the eye.
Type:
Grant
Filed:
April 22, 2002
Date of Patent:
February 7, 2006
Assignee:
Debiopharm S.A.
Inventors:
Roland Wenger, Manfred Mutter, Amaud Hamel, Francis Hubler
Abstract: Pharmaceutical, personal care and cosmetic compositions containing a tripeptide and a tetrapeptide are useful for treating visible signs of aging including wrinkles, stretch marks and dark circles.
Abstract: The invention relates to new basic amino acid derivatives of general formula I and the preparation and use thereof in treatment of pain. The compounds have histogranin-like antinociceptive, morphine potentiating and COX-2 induction modulating activities.
Type:
Grant
Filed:
February 7, 2002
Date of Patent:
December 6, 2005
Assignee:
University of Ottawa
Inventors:
Simon Lemaire, Irma Bernatchez-Lemaire, Hoang-Thanh Le
Abstract: Synthetic methods and compounds involving amino amides, peptides and peptidomimetics. Amino amide derivatives are prepared via the one-step three-component reaction of a glyoxamide, an amine, and an organoboron derivative. Conversion of the product to another glyoxamide intermediate allows the iterative use of this chemistry for the synthesis of peptides and peptidomimetics.
Abstract: A method of producing a biological fungicide composed of milk products, namely powdered cow milk, cow milk culture or bacteria culture, and a calcium carbonate. These components can be mixed to form a mixture, stored for long-term at below 32 degrees Fahrenheit or held below 75 degrees Fahrenheit for one month. Upon application of the mixture, fulvic acid may be added to the mixture.
Abstract: The present invention relates to a method for purifying a calcium ion-binding protein by cation exchange chromatography. The present invention provide a method for isolating and purifying a calcium ion-binding protein in a simple and efficient manner from a liquid sample containing a calcium ion-binding protein and contaminants without any pretreatment such as addition of a chelating agent. More specifically, the present invention relates to a method for purifying a calcium ion-binding protein which comprises contacting said protein with a cation exchange carrier in the presence of calcium ions to let the said protein be adsorbed to the carrier, and after washing, eluting said protein, and to a calcium ion-binding protein having substantially no contaminants obtained by the method of the present invention.
Type:
Grant
Filed:
July 18, 2001
Date of Patent:
March 22, 2005
Assignees:
Juridical Foundation The Chemo-Sero-Therapeutic Research Institute, Kowa Company, Ltd.
Abstract: The invention concerns compounds of general formula (I) wherein: R1 represents a hydrogen atom, a hydroxy radical, Ob or Ncd; A represents an oxygen atom, a CH2 radical or a NH radical; B represents the radical of a steroid; R3 represents a hydrogen atom, a methyl or hydroxyl radical; R4 represents a hydrogen atom or a hydroxyl radical; T represents a hydrogen atom, a methyl radical, a CH1CONH2, CH2C?N radical, a (CH2)2NH2 or (CH2)2Nalk+X?radical; X being a halogen atom and alc an alkyl radical; Y represents a hydrogen atom, a hydroxyl radical or a halogen atom or a OSO3H radical; W represents a hydrogen atom or a OH radical; Z represents a hydrogen atom or a methyl radical. The compounds of formula (I) exhibit antifungal properties.
Abstract: The present invention is a new and distinct primocane fruiting red raspberry cultivar named ‘Jaclyn’, which is capable of producing fruit much earlier than that of the standard cultivars. The cultivar is characterized by a vigorous suckering ability and its consistently large, dark, long conic and very symmetrical fruit. Fruit seldom sunscalds in the mid-Atlantic states when grown under standard irrigation and fertilization practices. Fruit aroma is very full, and fruit quality is excellent through even high temperatures. Fruit separation can be difficult in cooler weather.
Type:
Grant
Filed:
August 20, 2003
Date of Patent:
March 8, 2005
Assignees:
University of Maryland, University of Wisconsin, Virginia Tech Intellectual Properties, Inc.
Inventors:
Harry J. Swartz, Joseph A. Fiola, Herbert D. Stiles, Brian R. Smith